Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Jun Gong MD

Jun Gong MD

Assistant Professor, Department of Medicine, Division of Hematology and Oncology, Cedars-Sinai Medical Center, Los Angeles, California

Jun Gong, MD, is an Assistant Professor in the Department of Medicine, Division of Hematology and Oncology at Cedars-Sinai Medical Center. As a medical oncologist, his primary clinical interests are in gastrointestinal (GI), hepatobiliary, and genitourinary (GU) cancers with a multidisciplinary focus of care along with colleagues from surgery, gastroenterology, radiation oncology, radiology, and urology. Dr. Gong is focused on translational and clinical cancer research with interests in early therapeutic trials (immunotherapy, targeted therapies, biologics, and other systemic therapies) and biomarker development to improve patient outcomes in GI and GU cancers. 

Disclosures

Consultant or Advisory Role – EMD Serono, Elsevier, Exelixis, QED Therapeutics, Natera, Basilea, HalioDx, Eisai, Janssen, Astellas, Amgen, Pfizer, Seagen, and Bayer.

Recent Contributions to PracticeUpdate:

  1. Activity of Cabozantinib After Immune Checkpoint Blockade in Metastatic Clear Cell Renal Cell Carcinoma
  2. Neutrophil-to-Lymphocyte Ratio Predicts Outcomes in mRCC and mNSCLC Patients Treated With Nivolumab
  3. Optimizing Patient Selection for Cytoreductive Nephrectomy
  4. Neutrophil-to-Lymphocyte Ratio Predicts DFS in Postnephrectomy, High-Risk, Locoregional RCC
  5. The Systemic Immune-Inflammation Index in Patients With Metastatic RCC Treated With First-Line TKIs
  6. Elevated Serum γ-Glutamyltransferase Is Associated With Poor Prognosis in Patients With mRCC
  7. Salvage Ipilimumab and Nivolumab in Patients With mRCC After Prior Immune Checkpoint Inhibitors
  8. Safety and Efficacy of Immunotherapy Rechallenge in Patients With Renal Cell Carcinoma
  9. Anlotinib for Patients With mRCC Previously Treated With a VEGFR-TKI
  10. Efficacy of Savolitinib vs Sunitinib in Patients With MET-Driven Papillary Renal Cell Carcinoma

Elsewhere

Recently Updated